image
Healthcare - Biotechnology - NASDAQ - US
$ 18.27
-3.43 %
$ 895 M
Market Cap
-10.42
P/E
CASH FLOW STATEMENT
-73.2 M OPERATING CASH FLOW
-19.46%
-36 M INVESTING CASH FLOW
75.75%
133 M FINANCING CASH FLOW
-43.16%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Enliven Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -89 M
Depreciation & Amortization 317 K
Capital Expenditures -44 K
Stock-Based Compensation 20.2 M
Change in Working Capital -4.54 M
Others -5.47 M
Free Cash Flow -73.2 M

Cash Flow

Millions
Dec-2024 Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017
OPERATING CASH FLOW
Net Income (89.0) (71.6) (37.7) (24.7) (19.0) (23.5) (11.3) 0
Depreciation & Amortization 0.3 0.3 0.2 0.1 45 K 33 K 0 0
Deferred Income Tax 0 0 0 (3.8) 0 (0.2) 0 0
Stock Based Compensation 20.2 12.9 3.2 1.9 0.1 0.9 0.6 0
Other Operating Activities (0.1) (4.3) 1.7 3.8 9.7 0.2 0.8 (7.9)
Change in Working Capital (4.5) 1.4 0.4 3.6 0.6 0.7 1.2 (0.2)
Cash From Operations (73.2) (61.3) (32.1) (19.1) (8.5) (21.9) (8.8) (8.8)
INVESTING CASH FLOW
Capital Expenditures 44 K (0.1) (0.6) (0.2) (0.5) (0.1) 0 0
Other Items (36.0) (148.3) 0 0 0 (23.9) 0 0
Cash From Investing Activities (36.0) (148.4) (0.6) (0.2) (0.5) (24.1) 0 0
FINANCING CASH FLOW
Common Stock Repurchased 0 0 0 0 0 0 0 0
Total Debt Repaid 0 0 0 0 0 (2.0) 0 0
Dividends Paid 0 0 0 0 0 0 0 0
Other Financing Activities 94.0 234.3 (1.8) (1.2) 260.9 0 6.5 11.0
Cash From Financing Activities 133.2 234.3 (1.8) (1.0) 130.5 43.6 6.5 11.0
CHANGE IN CASH
Net Change In Cash 24.0 24.6 (34.5) (20.3) 121.5 (2.4) (2.3) 2.2
FREE CASH FLOW
Free Cash Flow (73.2) (61.4) (32.7) (19.3) (9.0) (22.0) (8.8) (8.8)